ResMed (RMD)
(Delayed Data from NYSE)
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Zacks News
ResMed (RMD) Q3 Earnings: Disappointment in the Cards?
by Zacks Equity Research
ResMed Inc. (RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.
ResMed's Study Results for Central Sleep Apnea Hold Promise
by Zacks Equity Research
ResMed Inc. (RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA).
Align Partners Zfx GmbH to Expand iTero Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) announced a non-exclusive agreement with digital prosthetic solutions maker, Zfx GmbH on iTero Element intraoral scanners.
VWR Corp Acquires EPL Archives, Improves Customer Service
by Zacks Equity Research
VWR Corporation (VWR) recently acquired the international biorepository services organization, EPL Archives, Inc.
PetMed Express' New Order Sales Disappoint, Competition Rife
by Zacks Equity Research
On Mar 23, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS).
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
by Zacks Equity Research
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
Walgreen Boots Buyout of Rite Aid Delayed, Other Woes Remain
by Zacks Equity Research
On Mar 24, we issued an updated research report on Illinois-based leading pharmacy-led, health and wellbeing enterprise, Walgreens Boots Alliance, Inc. (WBA).
Medtronic's (MDT) CoreValve Evolut Pro Receives FDA Approval
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently announced that it has received the FDA approval for its CoreValve Evolut PRO valve.
Hologic Completes Cynosure Buyout, Boosts Core Business
by Zacks Equity Research
Hologic, Inc. (HOLX) recently announced the completion of it earlier declared acquisition of marketer of aesthetic treatment systems, Cynosure, Inc.
Align's iTero Hits 1 Billion Mark, Boosts Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) has recently revealed that more than one million scans have been submitted using its iTero Element scanner in less than two years.
Genomic Health's Cancer Test Business Strong, Expenses High
by Zacks Equity Research
On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.
Integer (ITGR) Amends Term B Loan to Lower Interest Rate
by Zacks Equity Research
Integer Holdings Corporation (ITGR) announced that it has completed an amendment to its senior secured credit facilities to lower the interest rate on its Term B Loan Facility.
Genomic Health's Breast Recurrence Test Data Encouraging
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a leading molecular diagnostics company, recently presented results from 15 Oncotype DX Breast Recurrence Score studies.
Medtronic's Positive 2-Year SURTAVI Data Boosts Corevalve
by Zacks Equity Research
Medtronic plc (MDT) has released the first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial.
Abbott Laboratories' MitraClip Outcome Positive for DMR
by Zacks Equity Research
Abbott Laboratories (ABT) recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S.
Thermo Fisher Poised on Innovation, Global Growth Amid Woes
by Zacks Equity Research
On Mar 17, 2017, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
CVS Health Launches Reduced Rx for Affordable Medication
by Zacks Equity Research
CVS Health Corporation (CVS), a leading name in pharmacy benefit and retail pharmacy, recently announced the launch of a prescription savings program-Reduced Rx.
Medtronic's Melody TPV Wins FDA for Less-Invasive Treatment
by Zacks Equity Research
Medtronic plc (MDT) recently won FDA approval for Melody Transcatheter Pulmonary Valve for implantation in patients whose surgical bioprosthetic pulmonary heart valves have failed.
Align Technology Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $110.87 on Mar 15, eventually closing a bit lower at $110.31.
ResMed (RMD) Up 3.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed (RMD) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
ResMed Inc. (RMD) announced second-quarter fiscal 2017 adjusted earnings per share (EPS) of 73 cents, consistent with the prior-year quarter level.
Medical Product Stocks Q4 Earnings Roster: SYK, ISRG, RMD
by Zacks Equity Research
Medical is one of the broader sectors among the 16 Zacks sectors that is expected to report earnings growth in the fourth quarter.
ResMed (RMD) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
ResMed Inc. (RMD) is slated to report second-quarter fiscal 2017 results, after market close on Jan 23.
ResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders
by Zacks Equity Research
ResMed Inc. (RMD) recently formed a joint venture with renowned surgeon and television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors, L.P.
ResMed Achieves Key Milestone in Sleep-Disordered Breathing
by Zacks Equity Research
After one billion nights of sleep data was downloaded using ResMed's remote patient monitoring platform AirView, the company reached a landmark in the field of sleep research and treatment of sleep apnea.